The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling and is being developed for GPP, a rare orphan indication. Regulatory and patent exclusivity for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

・Vanda shares have rallied about 62% since mid-November, erasing the stock’s losses for the year amid a series of news flows. ・Tradipitant previously failed in gastroparesis but is now under FDA ...

Once again, Vanda Pharmaceuticals is challenging the FDA in court. This time, the company says the agency failed to give its application for Hetlioz in jet lag disorder a proper hearing after the FDA ...

Future Pak's most recent proposal to acquire Vanda was made on April 1, 2024. The offer was to buy Vanda for $7.25 to $7.75 per share. The low end of this range reflects a premium of 79% to Vanda's ...

A series of increasing buyout offers has failed to convince Vanda's board of directors that the company should sell itself. After receiving "unsolicited" buyout proposals from Michigan-based CDMO ...

Vanda Pharmaceuticals Inc. stock is down 17% since my July "hold" rating; the FDA approved Fanapt for bipolar I disorder, and stock jumped. The approval of Fanapt for bipolar disorder may not ...

The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a notice summarizing the grounds for refusing a new drug application (NDA) ...

Add The Drive (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results The car ...